Century Therapeutics, Inc. ((IPSC)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Century Therapeutics, Inc. is conducting the CALiPSO-1 study, officially titled A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases. This Phase 1 study aims to assess the safety and efficacy of CNTY-101 in treating refractory B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and diffuse cutaneous systemic sclerosis.
The study tests CNTY-101, a biological intervention administered intravenously, alongside IL-2 and lymphodepleting chemotherapy. CNTY-101 is designed to target CD19, a protein found on the surface of B cells, to help manage autoimmune conditions.
The study is interventional, non-randomized, and follows a sequential model with no masking. Its primary purpose is treatment, focusing on confirming the appropriate dosage and expanding its application.
Key dates include the study’s start on February 5, 2024, with the latest update on June 16, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
This update could positively influence Century Therapeutics’ stock performance by showcasing their innovative approach to autoimmune diseases. Investors may view this as a promising development, especially in comparison to competitors within the biotech industry.
The CALiPSO-1 study is ongoing, with further details available on the ClinicalTrials portal.